Your Single Source for Bioconjugation Discovery, Development and cGMP Manufacturing
WuXi XDC (stock code：2268.HK), a leading Contract Research, Development and Manufacturing Organization (CRDMO) focused on the global ADC and broader bioconjugate market, is a pioneering CRDMO offering integrated, end-to-end services. Services are provided from proximately located, state-of-the-art laboratories and manufacturing facilities, allowing for a significant reduction in development timelines and costs. Our over 2000 skilled employees work across a global network to deliver expert-driven, high-quality and right-first-time project execution for our customers. By offering a single-source, open-access platform with the most comprehensive capabilities and technologies, WuXi XDC enables our biopharmaceutical partners to speed the development of innovative therapies for the benefit of patients worldwide.